Maridebart cafraglutide

Maridebart cafraglutide (AMG 133) is an antibody-peptide conjugate acting as a GLP-1 receptor agonist and an antagonist of the GIP receptor. Maridebart cafraglutide reduces body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. Maridebart cafraglutide is promising for research of obesity[1][2].

Product Specifications

CAS Number

[2887445-76-1]

Product Name Alternative

AMG 133

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; GLP Receptor

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/maridebart-cafraglutide.html

Purity

99.24

Smiles

[Maridebartcafraglutide]

Molecular Weight

153,514 (average)

References & Citations

[1]Bloomgarden Z T. The 2023 WCIRDC: Obesity[J]. Journal of Diabetes, 2024, 16 (4) .|[2]Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6 (2) :290-303.